Education
About Us
Working with TipRanks
Follow Us
Hangzhou Tigermed Consulting Co., Ltd. Class H (DE:5HZ1)
FRANKFURT:5HZ1
5HZ1 Stock Chart & Stats
€5.70
-€0.08(-2.33%)
At close: 4:00 PM EST
€5.70
-€0.08(-2.33%)
Day’s Range― - ―
52-Week Range€2.78 - €6.40
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€5.79B
Enterprise Value€45.03B
Total Cash (Recent Filing)€1.71B
Total Debt (Recent Filing)€1.75B
Price to Earnings (P/E)64.1
Beta0.67
Next Earnings
Mar 31, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding123,124,800
10 Day Avg. Volume0
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)1.21
Price to Sales (P/S)3.79
P/FCF Ratio33.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.83Price Target Upside19.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and an equity-heavy capital base give the company financial flexibility to fund multi-year clinical projects, absorb R&D timing shocks, and pursue partnerships or acquisitions without immediate external financing, enhancing long-term resilience.
Consistent Free Cash FlowPersistent positive FCF and a high FCF-to-profit conversion (~84% of net income TTM) support reinvestment in operations, fund working-capital needs, and reduce reliance on external capital, strengthening the firm's ability to sustain service delivery and growth.
Leading CRO Franchise And PartnershipsA top-tier CRO position and established partnerships create durable client relationships, repeat project streams and barriers to entry for competitors, anchoring long-term demand as pharma/biotech outsourcing and trial complexity continue structurally rising.
Bears Say
Material Margin CompressionSharp multi-year margin decline erodes operating leverage and cash-generating capacity, implying weaker pricing power or higher cost intensity. Sustained margin pressure can impair reinvestment, returns and competitiveness across cyclical trial volumes.
Cash-to-earnings WeaknessOperating cash lagging reported profits suggests working-capital or timing strains and less durable cash backing for earnings. That raises financing friction risk for large program outlays and reduces margin of safety for payouts or M&A funding over the medium term.
Modest Return On EquityLow ROE despite a strong equity base indicates limited efficiency converting capital into returns. Over time this can constrain shareholder value creation, pressure capital allocation choices, and make growth less accretive unless operating profitability recovers.
Hangzhou Tigermed Consulting Co., Ltd. Class H News
5HZ1 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was €2.78 and its highest was €6.40 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is €5.79B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Mar 31, 2026 which is in 36 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Oct 28, 2025. The company reported €0.088 earnings per share for the quarter, beating the consensus estimate of €0.037 by €0.05.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H does not currently pay dividends.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.03.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of €0.088 in its last earnings report, beating expectations of €0.037. Following the earnings report the stock price went down -0.855%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in DE:5HZ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
1.40%
Trailing 12-Months
Asset Growth
-13.28%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. provides contract research organization services in the People's Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers regulatory submission and approval, medical translation, and good manufacturing practice (GMP) consulting services; and clinical services in the areas of medical science, early clinical and late phase development, medical monitoring, project management, patient recruitment, and quality management system. It also provides biometrics services comprising data management, biostatistics, and statistical programming; and integrated technology services, such as site management, pharmacovigilance, third party audit and training, medical imaging, clinical trial system solution, central laboratory, pre-clinical, and research hospital. Further, the company offers medical device/ in vitro diagnostics (IVD) services comprising medical device testing, regulatory submission, clinical evaluation and trials, GMP certificate, EU MDR and IVDR preparation, and value-added services; and post-marketing study, real world evidence, and vaccine clinical trial services. Hangzhou Tigermed Consulting Co., Ltd. was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
5HZ1 Stock 12 Month Forecast
Average Price Target
€6.83
▲(19.84% Upside)
Technical Analysis
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
Giant Biogene Holding Co. Ltd.
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---